HBOT for Hemorrhagic Radiation Cystitis After Pelvic Radiation

Blood in the urine that shows up months or years after radiation for prostate, cervical, bladder, or rectal cancer is one of the harder late effects to live with. The medical name is hemorrhagic radiation cystitis, and it falls under the FDA-cleared indication of delayed radiation tissue injury. HBOT is one of the treatments used when bleeding keeps coming back after other measures.

What Radiation Cystitis Is

Pelvic radiation treats the tumor, but the bladder sits in the field. Over time the radiation damages the small blood vessels in the bladder wall. The same “three H” pattern that drives osteoradionecrosis of the jaw applies here: the tissue becomes hypovascular (fewer working vessels), hypoxic (low oxygen), and hypocellular (few living cells).

Fragile new vessels form to compensate, and they bleed easily. That is why the hallmark of hemorrhagic radiation cystitis is visible blood in the urine, sometimes with clots, urgency, frequency, and pain on urination. The bleeding can be intermittent for years or severe enough to cause anemia and require transfusion or hospital admission.

Late radiation cystitis is delayed by design. The injury happened during treatment, but the consequences surface long after, often six months to several years out, occasionally a decade later. A person who finished radiation and felt fine can develop it without any warning.

How HBOT Fits Into Treatment

HBOT is an adjunct, not a first move. Urologists usually start with less involved measures: stopping the bleeding through the scope (cystoscopy with fulguration or clot evacuation), bladder irrigation, and medications. When bleeding is refractory, meaning it keeps returning despite those steps, HBOT becomes a reasonable option, and it is at that refractory stage that the trial evidence was gathered.

The mechanism is the same one that makes HBOT useful for radiation-damaged bone and soft tissue. Breathing 100 percent oxygen under pressure dissolves far more oxygen into the blood plasma than normal breathing allows. That oxygen reaches the hypoxic bladder wall and supports angiogenesis, the growth of new and more durable blood vessels, which over a course of treatment can reduce the bleeding from the fragile vessels already there. HBOT does not reverse the original radiation damage. It improves the environment so the tissue can do more of its own repair.

What the Research Shows

The strongest evidence for HBOT in radiation cystitis comes from a randomized controlled trial. Oscarsson et al. (2019), the RICH-ART trial published in Lancet Oncology, was a multicentre randomised controlled phase 2-3 study run across five Nordic hospitals. Patients with late radiation cystitis were assigned to HBOT plus standard care or standard care alone. The HBOT group reported significantly greater improvement in urinary symptoms, measured by the EPIC urinary score, and better health-related quality of life than the standard-care group. (PMID: 31537473)

The same research group reported long-term follow-up indicating that the symptom improvement seen in responders held up over several years rather than fading after treatment stopped.

The bladder findings sit alongside the closely related proctitis evidence. Clarke et al. (2008) ran a sham-controlled double-blind trial of HBOT for chronic refractory radiation proctitis, the rectal counterpart of cystitis, and found significant reductions in bleeding and improvement in quality of life in patients who had failed other treatments. (PMID: 18342453)

Reading these honestly, the trials studied patients whose bleeding was refractory to standard care. The benefit was meaningful but measured as symptom and quality-of-life improvement, not a guarantee that bleeding stops in every person. Some patients respond well and some do not, which is why HBOT is positioned as an adjunct after other measures rather than a standalone cure.

What a Course of Treatment Looks Like

Protocols vary, and your care team sets the plan for your situation. For radiation cystitis, courses commonly run 30 to 40 sessions, given daily on weekdays without surgery, at roughly 2.0 to 2.4 ATA for 90 to 120 minutes each. At a five-day-a-week schedule, a 40-session course takes about eight weeks. Our guide to HBOT session counts covers how protocols differ by condition and how progress is tracked along the way.

Improvement is gradual. Bleeding often eases over the course rather than all at once, and your team will reassess as treatment proceeds. Because radiation cystitis is a bladder problem rather than an open wound, evaluation relies on symptom reporting, urine findings, and cystoscopy rather than the wound measurements used for skin ulcers. For background on how HBOT supports radiation-damaged tissue more broadly, see our page on non-healing wounds.

Insurance Coverage

Delayed radiation injury, which includes hemorrhagic radiation cystitis, is an FDA-approved indication for HBOT. Medicare and many commercial insurers may cover it for qualifying patients when the diagnosis and the failure of standard treatment are documented in the clinical record. Coverage is not automatic, and prior authorization is the norm. Rates and policies change annually, so verify specifics with your facility’s billing team before you start. The broader radiation injury page explains how this indication sits within the other radiation complications HBOT is used for.

FAQ

Q: What is hemorrhagic radiation cystitis? Bladder bleeding from past pelvic radiation. Damaged vessels in the bladder wall become fragile and bleed, showing up as blood in the urine months to years after treatment.

Q: Does HBOT help radiation cystitis? It is FDA-approved as part of delayed radiation injury. The RICH-ART randomized trial (Oscarsson et al., 2019) found improved urinary symptoms and quality of life. It is used after other measures fail, and response varies.

Q: How many sessions are typical? Protocols vary, but 30 to 40 weekday sessions at about 2.0 to 2.4 ATA, 90 to 120 minutes each, is common. Your care team decides.

Q: Is it covered by insurance? It is an FDA-approved indication, so Medicare and many plans may cover it for qualifying patients with proper documentation. Verify with your facility’s billing team.

Related: Radiation Injury and HBOT | Osteoradionecrosis of the Jaw | How Many HBOT Sessions You Need

Sources:

• Oscarsson N, et al. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2-3 trial. Lancet Oncol. 2019;20(11):1602-1614. PMID: 31537473.
• Clarke RE, et al. Hyperbaric oxygen treatment of chronic refractory radiation proctitis: a randomized and controlled double-blind crossover trial with long-term follow-up. Int J Radiat Oncol Biol Phys. 2008;72(1):134-143. PMID: 18342453.
• Undersea and Hyperbaric Medical Society (UHMS). Delayed radiation injury (soft tissue and bony necrosis) among accepted indications for HBOT.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Hemorrhagic radiation cystitis requires evaluation and management by qualified physicians, typically a urologist working with a hyperbaric physician. Always consult your care team about your specific situation. This site does not establish a doctor-patient relationship.